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There is a long history of research into body fluid biomarkers in neurodegenerative and neuroinflammatory diseases. However,
only a few biomarkers in cerebrospinal fluid (CSF) are being used in clinical practice. Anti-aquaporin-4 antibodies in serum are
currently useful for the diagnosis of neuromyelitis optica (NMO), but we could expect novel CSF biomarkers that help define
prognosis and response to treatment for this disease. One of the most critical factors in biomarker research is the inadequate
powering of studies performed by single centers. Collaboration between investigators is needed to establish large biobanks of well-
defined samples. A key issue in collaboration is to establish standardized protocols for biobanking to ensure that the statistical
power gained by increasing the numbers of CSF samples is not compromised by pre-analytical factors. Here, consensus guidelines
for CSF collection and biobanking are presented, based on the guidelines that have been published by the BioMS-eu network for
CSF biomarker research.We focussed on CSF collection procedures, pre-analytical factors and high quality clinical and paraclinical
information. Importantly, the biobanking protocols are applicable for CSF biobanks for research targeting any neurological disease.
1. Introduction: The Need for Collaborative
Biobanking and Biomarker Studies
NMO can be diagnosed based on a blood-derived biomarker,
that is antibodies against aquaporin-4, a channel protein
present on astrocytes, extensively discussed in other con-
tributions in this special issue. The presence of antibodies
against aquaporin-4 has been proven as one of the most
successful results of biomarker studies, and is supportive for
the idea that central nervous system (CNS) abnormalities
are reflected in changes in body fluids. It also proofs the
autoimmune component of this disorder and of pathologies
that are related to the NMO spectrum disorders, such as
longitudinally extensive transverse myelitis.
Determination of serum anti-aquaporin-4 antibody lev-
els is a mainstay in the diagnosis of NMO, but the discovery
of such disease-specific antibodies is relatively recent [1],
and, therefore, further studies in body fluids are warranted.
One case report suggested that NMO-immunoglobulin
G (IgG), the NMO-associated antibodies that are reactive
to cerebellar tissue [1], can be absent in serum, but present
in CSF [2]. However, another study on a relative large
cohort of patients showed that testing CSF does not increase
diagnostic sensitivity [3]. Another recently identified can-
didate biomarker for NMO is glial fibrillary acid protein
(GFAP). Takano and colleagues observed that the analysis of
CSF glial fibrillary acid protein is useful in the diﬀerential
diagnosis between NMO and multiple sclerosis or acute
demyelinating encephalomyelitis, and that its CSF levels at
disease onset correlated with expanded disability score scale
(EDSS) in NMO [4]. However, studies on larger cohorts are
needed before drawing definite conclusions. Taken together,
no biomarkers are available yet for prognosis or therapy
response in NMO and in NMO-related disorders. Therefore,
biomarker studies on CSF are ongoing.
One important flaw in several previously performed
biomarker studies in CNS diseases has been the lack of large
cohorts to suﬃciently power the study. This is especially
an issue for such a rare disease as NMO, where a single
center will not be able to collect a large cohort within a
reasonable time frame. The need for collaboration was the
reason for biomarker researchers in Multiple Sclerosis to
start a network (BioMS-eu, http://www.bioms.eu/). The aim
of this collaboration is to obtain well-proven, high-quality
biomarkers, which will be achieved by sharing patient
samples, standardization, and improvement of procedures
important in the research area. One of the most urgent
prerequisites for collaboration was felt to be standardization
of biobanking protocols. Therefore, a consensus-meeting
was organised and the result was collection and biobanking
guidelines, which the network developed and published in
2009 [5]. There are currently major eﬀorts worldwide to
professionalize biobanks and the collection and biobanking
guidelines established by consensus among 26 groups par-
ticipating in BioMS-eu (http://www.bioms.eu/) is a major
achievement in the CNS biomarker field [5]. One year after
publication of the guidelines, over 90% of the BioMS-eu
laboratories had already adapted their procedures in agree-
ment with the guidelines. A great use of the guidelines is the
applicability for any neurological disease, including NMO,
and that it provides guidelines for setting up a novel biobank.
Furthermore, it will greatly facilitate biomarker studies in the
CNS biomarker research area. In the concensus discussions,
we have sought a balance between practicality and scientific
rationale, and the background of each decision is provided.
Before the consensus, it was clear that large diﬀerences were
present between collection protocols, highlighting the need
to address these diﬀerences (Figure 1 and Table 1). In the
current paper, we include only the items and their rationale
from the original paper that are relevant for biobanking
for NMO. Other modifications from the original protocol
is an adaptation of item 1 (samples should be pooled if
multiple collection tubes are used for one patient), and the
inclusion of an item addressing transportation (item 20) and
information of some more physiological confounders (item
25).
We would like to stress that researchers adhere to these
protocols for optimal collaboration in the field of CSF
biomarker research. We suggest using Tables 2 and 3 as a
checklist for CSF biomarker research and recommend that
future studies of CSF biomarker take these issues into
account. In discovery-based biomarker research, all these
items should be considered carefully before initiating a study.
Some procedures may not be possible in everyday clinical
practice (e.g., processing within one hour), but less stringent
requirements will suﬃce for specific research questions.
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Figure 1: Results of inventory of collection procedures among 14 European centers with CSF biobanks for MS research in 2006. (a) Other
body fluids that are collected simultaneously with CSF. Filled area indicates “yes”; open areas: not collected. (b) Storage temperature of
CSF and serum. Open area: −80; closed area: −20; grey area: not collected. (c) Average volume of CSF that is collected per patient per CSF
withdrawal. Bars indicate the average and ranges of volume per center. (d) Time-delay between CSF withdrawal, spinning and storage into
the freezer. Bars indicate the average and ranges of time per center.
Table 1: Results of inventory on collection protocols among 14 MS Biomarker Research Centers.
Procedure of CSF withdrawal Previous status among European CSF centers
Type of needle: 71% atraumatic, 21% traumatic, 8% both
Time of the day of withdrawal (important for markers
that are sensitive for circadian rhythm)
71% no specific day/time of withdrawal, 29% in the afternoon only
Temperature until storage 57% room temperature, 43% at 4◦C
Type of tube: 50% Sarstedt, 29% Eppendorf, 21% other
aliquoting: Range from 0.2mL to 2mL
(1) surveillance of freezers Present at 93% of the centers
(2) several freezers to split the samples (backup) Present at 14% of the centers
Therefore, careful documentation of these issues is crucial to
facilitate retrieval of appropriate samples dictated by specific
study aims. As indicated before, the procedures for with-
drawal and storage of CSF (Table 2) are broadly applicable
for any neurological disease.
Besides methodological issues, ethical approval is a cru-
cial prerequisite for collaboration between international
or national centers. The signed informed consent should
include a statement that exchange of samples between
(international) centers is allowed. Furthermore, to bring a
biomarker to clinical practice, one may need patents and
the involvement of industrial partners could be needed, who
have the infrastructure for large-scale production, quality
control procedures, and to reach as many laboratories as
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Table 2: Guidelines for procedure of CSF withdrawal.
Item
no.
Procedure Ideal situation
(A) Collection procedures
(1) Preferred volume
At least 12mL. First 1-2mL for basic CSF assessment (item 26). Last 10mL for
biobanking. Record volume taken and fraction used for biobanking, if applicable.
(2) Location Vertebral body L3–L5
(3) If bloody
Do not process further.
Criteria for bloody: more than 500 red blood cells/μL.
Record number of blood cells in diagnostic samples.
(4) Type of needle Atraumatic
(5) Type of collection tube Polypropylene tubes, screw cap, volume >10mL.
(6)
Time of day of withdrawal and
storage
Preferably standardized within each center allowing for intercenter diﬀerences in local
logistics.
Record date and time of collection.
(7)
Other body fluids that should be
collected simultaneously
Serum
(8)
Other body fluids that should be
collected simultaneously
Plasma: EDTA (preferred over citrate).
(B) Processing for storage
(9) Storage temperature until freezing Room temperature before, during, and after spinning.
(10) Spinning conditions
Serum: 2,000 g, 10min at room temperature.
CSF: 400 g, 10min at room temperature/2,000 g if no cells are to be preserved.
(11)
Time delay between withdrawal and
spinning and freezing
Optimal for CSF: 1-2 hours
Optimal for serum: 30–60min.
Thus doing “both body fluids simultaneously”: ideally within one hour.
After spinning, samples must be aliquoted and frozen immediately for storage at −80oC.
(12) Type of tube for aliquoting Small polypropylene tubes (1 to 2mL) with screw caps. Record manufacturer.
(13) Aliquoting
A minimum of two aliquots is recommended. The advised research sample volume of
10mL should be enough for >10 aliquots.
(14) Volume of aliquots
Minimum 0.1mL. Depending on total volume of tube: 0.2, 0.5, and 1mL. Preferably, the
tubes are filled up to 75%.
(15) Coding
Unique codes. Freezing-proof labels. Ideally barcodes to facilitate searching, to aid in
blinding the analysis and to protect the privacy of patients.
(C) Storage conditions and administration
(16) Freezing temperature −80oC
(17)
Additional items on sample
collection protocols that must be
recorded
Location of samples
(18)
Additional items on sample
collection protocols that must be
recorded
Surveillance of freezers
(19)
Additional items on sample
collection protocols that must be
recorded
Splitting of samples over two or more freezers
(20) Transport conditions
Always on dry-ice, suﬃcient volume of dry-ice for minimal 3 days of transport.
Initiated on Mondays.
Avoid high temperatures for thawing and mix thoroughly.
possible. For large-scale validation studies, patient samples
are of course also needed, and it will be wise to consider this
possibility at the start of biobank formation and, if ethical
laws permit and the option is perceived to be important,
indicate the possibility for industrial cooperation in the
patient information and consent.
Lastly, researchers should be willing to share their sam-
ples and information for the benefit of the whole, that is,
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Table 3: Guidelines for patient information requirement in databases of MS patients.
Item
no.
(D) Patient information requirement in databases
(a) Basic demographics
(21) (1) date of birth (age if date of birth is not available)
(22) (2) Gender
(23) (3) Ethnicity
(24) (4) Use of drugs, at sampling and year before sampling.
(25) (5) Actual nonneuronal infections, fasting or nonfasting, pregnancy.
(26)
(6) Basic CSF analysis (CSF cell count, diﬀerential cytology, erythrocyte count, oligoclonal IgG
bands (which is at least two bands by definition), albumin ratio, total protein (if albumin is not
measured), and IgG index)
(7) Record the methods of routine analysis
(27) (8) The data in the CSF database should be in English and use Standardized International Units
obtaining reliable biomarkers that can be used for patient
care and cure.
2. Guidelines for CSF Biobanking for
Biomarker Research, Rationale, and Details
2.1. Procedure of CSF Collection (Table 2)
(A) Collection Procedures:
Item 1 Volume of Withdrawal of at Least 12mL. The CSF
volume taken can influence the concentration of biomarkers.
Most molecules and cell numbers have a rostrocaudal con-
centration gradient [6, 7]. If a small volume is taken, the
CSF will reflect the composition of the lumbar dural sac,
whereas large volumes may reflect the rostral spinal or even
ventricular CSF. Therefore, if biomarker concentrations in a
sample from a puncture of 2mL are compared to that in a
puncture of 15mL, this can lead to erroneous results. Also
collecting diﬀerent portions of the CSF for biobanking (e.g.,
initial and final volumes of the puncture) may introduce
errors. Thus, a standard volume of CSF should be collected
during lumbar puncture, the first 2mL can be used for basic
CSF analysis (item 26), and the remainder of the sample
should be pooled before spinning and aliquoting. At least,
the procedure must be recorded. The volume of collected
CSF does not correlate with the risk of postlumbar puncture
headache [8, 9].
Item 2 Location of Puncture: Vertebral Body L3–L5. Usually,
diagnostic CSF is obtained by lumbar puncture. Because
of the increasing gradient in protein concentration from
ventricular to lumbar CSF [10], the site of CSF withdrawal
must be recorded. When CSF is taken from other locations
such as the cervical cisterns or from the lateral ventricles (e.g.,
ventricular drainage), this should be documented.
Item 3 Removal of Bloody CSF Samples. A traumatic tap caus-
ing blood contamination of CSF occurs in about 14–20%
of standard lumbar punctures [11]. For biomarkers that
have high serum concentrations, such as coagulation factors,
blood contamination can lead to false positive results. In
addition, blood proteins lead to suppressed matrix-assisted
laser desorption/ionization-mass spectrometry (MALDI-
TOF/MS) proteomics patterns in CSF. This suppression by
blood proteins is, however, highly reduced after removal of
the blood cells by centrifugation prior to initial freezing [12,
13]. Recording of erythrocyte count is essential to select CSF
samples appropriate for these measurements. CSF samples
with an erythrocyte count above 500/μL should not be used
for biomarker studies.
Item 4 Use of Atraumatic Needle (Sprotte or Whitacre Needle).
There is no evidence that the type of lumbar puncture needle
influences biomarker concentrations. However, atraumatic
needles are best tolerated by patients, and are associated with
a lower risk for postlumbar puncture headache, that is about
12% for a needle size of 20–22G compared to about 70% for
a needle size of 16–19G [14, 15].
Item 5 Use of Polypropylene Collection Tubes. There are sev-
eral reports showing that the type of collection tube influ-
ences biomarker outcomes, for example, total tau proteins
and amyloid β peptides [16]. Therefore, standardization is
important. We propose to use polypropylene tubes, with
their low protein binding potential, for collecting CSF. No
additives should be used. Glass tubes should be avoided, due
to safety reasons for personnel. When multiple tubes are
used, the total volume should be mixed after centrifugation
to avoid gradient eﬀects.
Item 6 Time of the Day of Withdrawal. For biomarkers that
are influenced by circadian rhythm, time of withdrawal is
important [17]. Since it is often diﬃcult to accomplish stan-
dardization of withdrawal time in everyday clinical practice,
documentation is necessary to select the appropriate samples
to minimize the eﬀect of this variable.
Items 7 and 8 Serum, Plasma, and DNA Linked to the CSF
Sample. It is important to collect matched serum and/or
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plasma samples for evaluation of CSF biomarkers because
the concentration of the marker in blood often influences
that in CSF [18]. Further, serum/plasma pairs are essential
to study the intrathecal origin of a biomarker and its CNS
specificity. Furthermore, the presence of CNS markers in
serum/plasma may aid in disease monitoring. Vacuum tubes
that use EDTA (in dried format) are preferred over those
that use citrate (in solution) because if tubes containing a
standard volume of citrate are filled incompletely, the final
biomarker concentration is diluted unequally compared to
other samples. Depending on the type of biomarkers and
methods of study, we recommend collecting both serum and
plasma [19]; for some methods, plasma is preferred over
serum and vice versa. Serum/plasma samples should not
be haemolysed. We advise to perform a blood draw using
vacuum systems, since tourniquet use is related to additional
confounding factors in the preanalytic phase include tourni-
quet time and posture [20]. Furthermore, instructions of the
supplier should be followed, such as mixing.
Lastly, DNA collection expands the possibilities for
studying the phenotypes and genotypes within individuals.
A protocol for storage and handling of DNA can be found in
the supplementary files (E-Appendix 1).
(B) Processing for Storage:
Item 9 Storage at Room Temperature Until Spinning and
Aliquoting. For CSF, there are no data available yet that sup-
port a preference for leaving the samples at room temper-
ature or at 4◦C until processing. For serum/plasma prepro-
cessing temperature is more crucial. To avoid platelet acti-
vation [21], serum/plasma samples should be kept at room
temperature before centrifugation. Therefore, processing at
room temperature for both serum/plasma and CSF, includ-
ing during and after spinning, is suitable for most studies.
Relatively few systematic studies have been performed on this
issue. We would recommend exploratory studies to define
the eﬀect of temperature on specific biomarkers.
Item 10 Standardized Spinning Conditions. We propose to
adhere to a standardized spinning protocol of 400 g for 10
minutes at room temperature when fragile cells need to be
preserved for RNA of cell isolation, and otherwise at 2,000 g.
For serum/plasma, we propose to spin at 2,000 g for 10min at
room temperature. Standardization of spinning temperature
and speed may be important for some biomarkers, although
no studies have addressed these specific preanalytical vari-
ables for CSF. For plasma and serum, temperature of
processing is known to be critical for specific biomarkers
[22]. After centrifugation, the supernatant must be aliquoted
and stored immediately. If this is not done, the processing
time should be documented.
Item 11 Standardization of Time-Delay between Withdrawal,
Spinning, and Freezing. Studies of the eﬀects of preanalytical
variables byMALDI-TOF/MS proteomics (proteins/peptides
<20 kD) have shown that the time between sampling and
storage is more crucial for specific serum proteins or peptides
than for CSF, [12, 13, 23]. For CSF, it was observed that
processing within two hours does not lead to artefactual
results [12, 13]. For serum, it was observed that small
diﬀerences in processing time (∼10–30min) can result in
changes in the protein profile [19]. Some biomarkers, such
as antibodies or specific cytokines, are not very sensitive to
sampling and storage conditions [24]. For practical reasons,
and in view of the standard of 30–60min clotting time for
serum, we recommend a time delay of 1.5 hours (±30min)
for both matrices. When CSF cells are to be preserved,
processing as soon as possible is to be advised as cell
numbers decrease quickly. However, in most of the centers,
processing of the body fluid samples within one hour is
not common practice. Therefore, documentation of time
of withdrawal and storage is required in order to select
uniform samples. For newly discovered biomarkers, these
preanalytical variables should be evaluated.
Item 12 Use of Small Polypropylene Tubes for Aliquoting. Due
to the same rationale as for CSF withdrawal (item 5), we
recommend that polypropylene tubes should be used for
aliquoting and storage. Furthermore, vials with screw caps
should be used for a secure sealing. The proposed tube size is
0.25, 0.5, and 1mL.
Item 13 Aliquoting. Freeze/thaw cycles can influence bio-
marker concentrations [25]. For example, one-time freezing
of CSF samples can lead to a highly significant loss of amyloid
β(1-42) which is decreased a further 20% after three more
thawing cycles [26, 27]. By contrast, no eﬀects on CSF
proteome profiles obtained by MALDI-TOF/MS have been
observed after up to four freeze/thaw cycles [13].
In principle, repeated freeze/thawing of samples should
be avoided, as data addressing this topic are available for
only a few biomarkers and the response to freeze/thaw cycles
of new biomarkers is not known. Thus, splitting the pooled
sample in multiple small aliquots is optimal, and possible
freeze/thaw cycles should be recorded.
Item 14 Volumes of Aliquots of 0.2, 0.5, and 1mL. Small
aliquot volumes are optimal to avoid freeze/thawing and
to avoid waste of CSF. Tubes should be filled up to 75%
to prevent freeze-drying within the tube, which will aﬀect
the concentration of biomarkers, although it may only be a
problem if the seal of the cryogenic tubes are not airtight.
This issue has not been formally studied and is not referred
to in related standard operating procedures [28].
Item 15 Coding and Use of Freezing-Proof Labels. Unique
codes are necessary to track samples and pair with clinical
data. Ideally barcodes should be used to facilitate searching,
to aid in blinding the analysis, and to protect the privacy of
patients. It is important to have center-unique codes, to track
data retrospectively. Labels must be water and frost (−80◦C)
resistant.
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(C) Storage and Administration of Samples (Table 2, Lower
Part):
Item 16 Freezing Temperature of −80◦C. Proteins may not be
stable at −20◦C for years. In one study, the eﬀect of storing
CSF at −20◦C and −80◦C on cystatin C, an abundant CSF
protein, was investigated. Cleavage of this protein occurred
in all samples stored at −20◦C but not in samples stored at
−80◦C [29]. Apart from the cystatin C truncation, changes
in the low molecular weight polypeptide profile due to CSF
sample storage at −20◦C for three months appeared to be
minimal [12, 13]. Oligoclonal bands in CSFmay be recovered
after several years of storage at −20◦C indicating a high
stability of immunoglobulins. Nevertheless, self-defrosting
freezers must not be used. No data are available showing the
benefit of storage of CSF or serum in liquid nitrogen. As this
is expensive and not practical for CSF biobanking, there is no
basis yet to recommend storage in liquid nitrogen.
Taken together, we recommend that samples are stored at
−80◦C to ensure long-term stability of biomarkers.
Item 17 Location of Samples. To enable easy tracking and fast
relocation of samples, storage information should include
freezer location, freezer identification, and sample location
within freezer.
Items 18 and 19: Surveillance of Freezers and Splitting of
Samples. Freezers should be alarm controlled and a sample
rescue plan established and documented. All freezers must
be registered in a freezer log file. Ideally, daily temperature
logs should be available for all freezers. Aliquots of samples
should be distributed among diﬀerent freezers, although not
absolutely needed if good surveillance is in place. An empty,
an empty back-up freezer should be available.
Item 20: Transport Conditions and Thawing before Use.
Transport of frozen samples should always be performed on
dry-ice, and the volume should be suﬃcient for transport
for minimal 3 days. Preferably, transports are initiated on
Monday for the samples to arrive within the same week.
Once the samples have arrived and are ready for experi-
ments, excessive thawing temperatures (such as 37◦C) are
to be avoided to prevent protein degradation. Furthermore,
inadequate agitation can cause salt and protein gradients to
form in thawed samples.
(D) Patient Information Requirement in Database:
Items 21-22 Basic Demographics, such as Age and Gender.
Information on the age at sampling is needed to allow
comparability to age-matched reference values, since many
proteins show age-dependent changes, for example, albumin
or IgG [30]. Ideally, date of birth and date of sampling are
recorded. Gender has to be provided due to variability of
markers influenced by hormones.
Item 23 Ethnicity. Reference ranges of biomarkers can be
influenced by the genetic status [31]. For example, a recent
study observed a higher IgG index in African Americans
than in Caucasians, unrelated to socioeconomic status [32].
Criteria for race and ethnicity are available via the website of
the National Institutes of Health [33].
Item 24 Treatment at Sampling and Year before Sampling.
It is well known that commonly used drugs for treatment
of MS, including immunomodulatory agents and use of
methylprednisolone for treatment or prevention of relapses,
have an influence on expression of biomarkers [34, 35].
Other treatments could likewise influence biomarker results
in NMO patients. Therefore, type and duration of treatment
should be documented in detail, preferably beginning at least
one year before CSF collection.
Item 25 Fasting, Infections and Pregnancies. Other relevant
physiological variables that can influence CSF and blood
analyte levels should be recorded including fasting versus
non fasting, pregnancy, and underlying nonneurological
conditions such as infections [20].
Item 26 Basic CSF Analysis (Protein, Cell Counts, Erythrocytes,
Etc. . .). To enable stratification of patients according to their
CSF findings and to evaluate suitability of samples for further
analysis, results of basic CSF analysis should be recorded.
Primarily, the CSF profile serves for exclusion of other
diseases. In addition, quantitative changes of immunological
markers are likely to occur depending on disease stage,
relapse activity, and medication. Inflammatory processes
may influence the blood-CSF barrier function and thereby
biomarker concentrations [18].
The presence of Oligoclonal IgG bands (OGB) in NMO is
quite distinct from that in MS in that OGBs in MS are persis-
tent, while they are transient in NMO [36, 37]. For example,
OGBs were detected in 399 of 411 MS patients (97%) and
never disappeared. In NMO, OGBs were detected in three of
11 patients (27%) and always disappeared. The sensitivity of
oligoclonal IgG bands is strongly dependent on the method
used. We strongly recommend isoelectric focusing followed
by immunoblotting and staining for IgG [38, 39]. Preferably,
the methods of all routine diagnostic procedures, including
oligoclonal banding, should be documented.
Item 27 Data in the CSF Database in English. The mask on
the database screen could be in the local language, but the
underlying files will need to be in English. It is strongly
suggested to use a commercially available program, if not a
common database for networks like BioMS-eu. The database
should also adhere to standardized international units.
3. Concluding Remarks
The lists provided in Table 2 can be used as an easy checklist
for CSF biobanking for any CNS disease, applicable during
setup of the procedures and also as a checklist for recording
sample characteristics. It is expected that these standard-
izations will pave the way for large biomarker studies and
fruitful collaborations. In the original paper, we present
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guidelines for outcome measures to be included for MS
biomarker studies [5]. For NMO, standardisation of outcome
measures is still needed. Ultimately, these endeavors are to
arrive at validated biomarker assays for diagnosis, prognosis,
and treatment of CNS diseases and a potential to elucidate
relevant disease mechanisms.
Acknowledgments
Other participants of the BioMS-eu meeting in London,
March 2007, are acknowledged for their contribution to
the discussions resulting in this guideline: H. Abderrahim,
S. Al-Izki, D. Baker, R. Banks, Y. Ben-Schloma, A. Berthele,
A. Bertolotto, R. Farrell, J. Furby, R. Gani, F. Gilli, S. Gnana-
pavan, B. Gomez, B. Greco, E. Hauben, E. Havrdova, T. Hay-
ton, E. Iacobaeus, A. Jaber, N. Jafari, S. Jackson, R. Kapoor, G.
Keir, A. Kok, A. Konieczny, A. Kroksveen, V. Lampasona, R.
Lindberg, A. Lockhart, C. Luk, C.Maggiore,M.Mauritzio, A.
Millonig, H. Parkes, T. Plitz, D. Sadovnik, A. Sala, R. Sachse,
K. Schmierer, K. Smith, S. Suessmith, P. Thompson, H. L.
Weiner, B. Wilson, D. Wright, J. Zajicek, and P. Zaratin.
References
[1] P. V. A. Lennon, D.M.Wingerchuk, T. J. Kryzer et al., “A serum
autoantibodymarker of neuromyelitis optica: distinction from
multiple sclerosis,” The Lancet, vol. 364, no. 9451, pp. 2106–
2112, 2004.
[2] E. C. Klawiter, E. Alvarez, J. Xu et al., “NMO-IgG detected in
CSF in seronegative neuromyelitis optica,” Neurology, vol. 72,
no. 12, pp. 1101–1103, 2009.
[3] S. Jarius, D. Franciotta, F. Paul et al., “Cerebrospinal fluid
antibodies to aquaporin-4 in neuromyelitis optica and related
disorders: frequency, origin, and diagnostic relevance,” Journal
of Neuroinflammation, vol. 7, article 52, 2010.
[4] R. Takano, T. Misu, T. Takahashi, S. Sato, K. Fujihara, and Y.
Itoyama, “Astrocytic damage is far more severe than demyeli-
nation in NMO: a clinical CSF biomarker study,” Neurology,
vol. 75, no. 3, pp. 208–216, 2010.
[5] C. E. Teunissen, A. Petzold, J. L. Bennett et al., “A consensus
protocol for the standardization of cerebrospinal fluid collec-
tion and biobanking,” Neurology, vol. 73, no. 22, pp. 1914–
1922, 2009.
[6] H. Reiber, “Dynamics of brain-derived proteins in cere-
brospinal fluid,” Clinica Chimica Acta, vol. 310, no. 2, pp. 173–
186, 2001.
[7] G. Martino, L. M. E. Grimaldi, L. Moiola et al., “Discontin-
uous distribution of IgG oligoclonal bands in cerebrospinal
fluid from multiple sclerosis patients,” Journal of Neuroim-
munology, vol. 30, no. 2-3, pp. 129–134, 1990.
[8] B. Grant, B. Condon, I. Hart, and G. M. Teasdale, “Changes
in intracranial CSF volume after lumbar puncture and their
relationship to post-LP headache,” Journal of Neurology Neu-
rosurgery and Psychiatry, vol. 54, no. 5, pp. 440–442, 1991.
[9] K. M. Kuntz, E. Kokmen, J. C. Stevens, P. Miller, K. P. Oﬀord,
and M. M. Ho, “Post-lumbar puncture headaches: experience
in 501 consecutive procedures,” Neurology, vol. 42, no. 10, pp.
1884–1887, 1992.
[10] E. J. Thompson, The CSF Proteins: A Biochemical Approach,
Elsevier, Amsterdam, The Netherlands, 2005.
[11] A. Petzold, L. T. Sharpe, and G. Keir, “Spectrophotometry for
cerebrospinal fluid pigment analysis,” Neurocritical Care, vol.
4, no. 2, pp. 153–162, 2006.
[12] F. S. Berven, A. C. Kroksveen, M. Berle et al., “Pre-analytical
influence on the low molecular weight cerebrospinal fluid
proteome,” Proteomics—Clinical Applications, vol. 1, no. 7, pp.
699–711, 2007.
[13] C. R. Jimenez, M. Koel-Simmelink, T. V. Pham, L. van der
Voort, and C. E. Teunissen, “Endogeneous peptide profiling of
cerebrospinal fluid by MALDI-TOF mass spectrometry: opti-
mization of magnetic bead-based peptide capture and analysis
of preanalytical variables,” Proteomics—Clinical Applications,
vol. 1, no. 11, pp. 1385–1392, 2007.
[14] E. R. Peskind, R. Riekse, J. F. Quinn et al., “Safety and accept-
ability of the research lumbar puncture,” Alzheimer Disease
and Associated Disorders, vol. 19, no. 4, pp. 220–225, 2005.
[15] D. Carson and M. Serpell, “Choosing the best needle for
diagnostic lumbar puncture,”Neurology, vol. 47, no. 1, pp. 33–
37, 1996.
[16] P. Lewczuk, G. Beck, H. Esselmann et al., “Eﬀect of sample
collection tubes on cerebrospinal fluid concentrations of tau
proteins and amyloid β peptides,” Clinical Chemistry, vol. 52,
no. 2, pp. 332–334, 2006.
[17] E. Murillo-Rodriguez, F. De´sarnaud, and O. Prospe´ro-Garcı´a,
“Diurnal variation of arachidonoylethanolamine, palmi-
toylethanolamide and oleoylethanolamide in the brain of the
rat,” Life Sciences, vol. 79, no. 1, pp. 30–37, 2006.
[18] F. Deisenhammer, A. Bartos, R. Egg et al., “Guidelines on
routine cerebrospinal fluid analysis. Report from an EFNS task
force,” European Journal of Neurology, vol. 13, no. 9, pp. 913–
922, 2006.
[19] C. R. Jimenez, S. Piersma, and T. V. Pham, “High-throughput
and targeted in-depth mass spectrometry-based approaches
for biofluid profiling and biomarker discovery,” Biomarkers in
Medicine, vol. 1, pp. 541–565, 2007.
[20] S. Narayanan, “The preanalytic phase: an important com-
ponent of laboratory medicine,” American Journal of Clinical
Pathology, vol. 113, no. 3, pp. 429–452, 2000.
[21] G. Scharbert, M. Kalb, C. Marschalek, and S. A. Kozek-
Langenecker, “The eﬀects of test temperature and storage
temperature on platelet aggregation: a whole blood in vitro
study,” Anesthesia and Analgesia, vol. 102, no. 4, pp. 1280–
1284, 2006.
[22] A. F. Lomholt, C. B. Frederiksen, I. B. J. Christensen, N.
Bru¨nner, and H. J. Nielsen, “Plasma tissue inhibitor of meta-
lloproteinases-1 as a biological marker? Pre-analytical consid-
erations,” Clinica Chimica Acta, vol. 380, no. 1-2, pp. 128–132,
2007.
[23] M. West-Nielsen, E. V. Høgdall, E. Marchiori, C. K. Høgdall,
C. Schou, and N. H. H. Heegaard, “Sample handling for
mass spectrometric proteomic investigations of human sera,”
Analytical Chemistry, vol. 77, no. 16, pp. 5114–5123, 2005.
[24] G. Kenis, C. Teunissen, R. De Jongh, E. Bosmans, H. Stein-
busch, and M. Maes, “Stability of interleukin 6, soluble
interleukin 6 receptor, interleukin 10 and CC16 in human
serum,” Cytokine, vol. 19, no. 5, pp. 228–235, 2002.
[25] C. Chaigneau, T. Cabioch, K. Beaumont, and F. Betsou,
“Serum biobank certification and the establishment of quality
controls for biological fluids: examples of serum biomarker
stability after temperature variation,” Clinical Chemistry and
Laboratory Medicine, vol. 45, no. 10, pp. 1390–1395, 2007.
[26] N. S. M. Schoonenboom, C. Mulder, H. Vanderstichele et al.,
“Eﬀects of processing and storage conditions on amyloid β (1-
42) and tau concentrations in cerebrospinal fluid: implications
Multiple Sclerosis International 9
for use in clinical practice,” Clinical Chemistry, vol. 51, no. 1,
pp. 189–195, 2005.
[27] M. Bibl, H. Esselmann, M. Otto et al., “Cerebrospinal fluid
amyloid β peptide patterns in Alzheimer’s disease patients
and nondemented controls depend on sample pretreatment:
indication of carrier-mediated epitope masking of amyloid β
peptides,” Electrophoresis, vol. 25, no. 17, pp. 2912–2918, 2004.
[28] M. K. Tuck, D. W. Chan, D. Chia et al., “Standard operating
procedures for serum and plasma collection: early detection
research network consensus statement standard operating
procedure integration working group,” Journal of Proteome Re-
search, vol. 8, no. 1, pp. 113–117, 2009.
[29] O. Carrette, P. R. Burkhard, S. Hughes, D. F. Hochstrasser,
and J. C. Sanchez, “Truncated cystatin C in cerebrospiral fluid:
technical artefact or biological process?” Proteomics, vol. 5, no.
12, pp. 3060–3065, 2005.
[30] M. J. Garton, G. Keir, M. Vijaya Lakshmi, and E. J. Thompson,
“Age-related changes in cerebrospinal fluid protein concentra-
tions,” Journal of the Neurological Sciences, vol. 104, no. 1, pp.
74–80, 1991.
[31] J. M. Moulds, “Ethnic diversity of class III genes in autoim-
mune disease,” Front Biosci, vol. 6, pp. D986–D991, 2001.
[32] J. R. Rinker, K. Trinkaus, R. T. Naismith, and A. H. Cross,
“Higher IgG index found in African Americans versus Cau-
casians with multiple sclerosis,” Neurology, vol. 69, no. 1, pp.
68–72, 2007.
[33] http://grants.nih.gov/grants/guide/notice-files/NOT-OD-01-
053.html.
[34] S. T. F. M. Frequin, F. Barkhof, K. J. B. Lamers, O. R. Hommes,
and G. F. Borm, “CSF myelin basic protein, IgG and IgM
levels in 101 MS patients before and after treatment with
high-dose intravenous methylprednisolone,” Acta Neurologica
Scandinavica, vol. 86, no. 3, pp. 291–297, 1992.
[35] P. Rieckmann, B. Altenhofen, A. Riegel, B. Kallmann, and
K. Felgenhauer, “Correlation of soluble adhesion molecules
in blood and cerebrospinal fluid with magnetic resonance
imaging activity in patients with multiple sclerosis,” Multiple
Sclerosis, vol. 4, no. 3, pp. 178–182, 1998.
[36] G. Piccolo, D. M. Franciotta, C. Camana et al., “Devic’s
neuromyelitis optica: long-term follow-up and serial CSF
findings in two cases,” Journal of Neurology, vol. 237, no. 4,
pp. 262–264, 1990.
[37] R. Bergamaschi, S. Tonietti, D. Franciotta et al., “Oligoclonal
bands in Devic’s neuromyelitis optica and multiple sclerosis:
diﬀerences in repeated cerebrospinal fluid examinations,”
Multiple Sclerosis, vol. 10, no. 1, pp. 2–4, 2004.
[38] M. Andersson, J. Alvarez-Cermeno, G. Bernardi et al., “Cere-
brospinal fluid in the diagnosis of multiple sclerosis: a consen-
sus report,” Journal of Neurology Neurosurgery and Psychiatry,
vol. 57, no. 8, pp. 897–902, 1994.
[39] M. S. Freedman, E. J. Thompson, F. Deisenhammer et al.,
“Recommended standard of cerebrospinal fluid analysis in
the diagnosis of multiple sclerosis: a consensus statement,”
Archives of Neurology, vol. 62, no. 6, pp. 865–870, 2005.
